Industry Signals
EW$101.85-1.95%
MDT$99.94-0.67%
ABT$103.00-0.84%
BSX$41.98-2.35%
SYK$310.00-0.98%
ZBH$101.10-0.36%
RMD$235.63-0.53%
ICHR$27.28-15.15%
Previous close · Nov 22

Latest News

View all news
CVB
news·2 days ago·Cardiovascular Business

Self-expanding TAVR valves from Medtronic, Abbott consistently linked to positive outcomes

Self-expanding TAVR valves from Medtronic and Abbott demonstrate consistent positive clinical outcomes in comparative analyses. The findings support the sustained performance profile of these platforms in transcatheter aortic valve replacement procedures.

Digest: These data reinforce operator confidence in self-expanding valve technology and may influence device selection strategies among interventional cardiologists, particularly in anatomies where self-expanding platforms offer theoretical advantages.

TAVRMedtronicAbbottMarketRead original
CVB
trial·3 days ago·Cardiovascular Business

Abbott kicks off new research on software-guided, balloon-expandable TAVR system

Abbott has initiated new research on a software-guided, balloon-expandable transcatheter aortic valve replacement system. No specific clinical data or trial endpoints were provided in the article content.

Digest: Abbott's entry into balloon-expandable TAVR with software guidance could challenge Edwards and Medtronic's market dominance and potentially improve procedural precision and outcomes.

TAVRAbbottTrialImagingRead original
Healio Cardiology
trial·9 days ago·Healio Cardiology

Device shows benefit in severe tricuspid regurgitation

The CLASP II TR trial randomized 450 patients with symptomatic severe tricuspid regurgitation to transcatheter tricuspid valve repair with the Pascal Precision system (Edwards Lifesciences) versus optimal medical therapy alone. At 1 year, the device improved health status and reduced TR severity compared with medical therapy, though no significant difference was observed in mortality or heart failure hospitalization.

Digest: This represents the first randomized controlled trial data for the FDA-approved Pascal Precision system in tricuspid regurgitation, providing evidence for transcatheter intervention in a valve position historically undertreated and associated with poor outcomes.

TTVREdwardsTrialFDARead original
DIC
trial·17 days ago·Diagnostic & Interventional Cardiology

Abbott Begins Enrollment in Global Trial of Investigational Mitral Valve Replacement System

Abbott has initiated enrollment in a global clinical trial evaluating its investigational transcatheter mitral valve replacement system. No specific enrollment targets, trial design details, or timeline information were provided in the article.

Digest: This represents Abbott's strategic entry into the competitive TMVR market, currently dominated by early-stage investigational devices from Edwards and Medtronic.

TMVRAbbottTrialRead original
DIC
industry·17 days ago·Diagnostic & Interventional Cardiology

GE HealthCare Introduces Ceiling-Mounted Image Guiding System

GE HealthCare has launched a ceiling-mounted image guiding system for interventional procedures. No specific clinical performance data or technical specifications were provided in the brief announcement.

Digest: Advanced imaging systems are critical infrastructure for structural heart interventions including TAVR and TMVR, potentially improving procedural visualization and workflow efficiency.

ImagingMarketRead original
Healio Cardiology
research·19 days ago·Healio Cardiology

TAVR benefits high-risk patients with moderate aortic stenosis

The PROGRESS trial demonstrated that TAVR with a balloon-expandable valve reduced the risk of death or heart failure events at 2 years compared with clinical surveillance in high-risk patients with moderate aortic stenosis and at-risk features. The primary safety outcome at 30 days occurred in 5.9% of patients, meeting the performance goal, while the primary effectiveness outcome at 2 years occurred in 16.7% of the TAVR group.

Digest: This randomized trial challenges current practice by demonstrating clinical benefit of early intervention in moderate aortic stenosis, potentially expanding TAVR indications beyond severe disease in selected high-risk patients.

TAVRTrialHigh RiskEdwardsRead original
AHA Heart News
news·20 days ago·AHA Heart News

Deaths from heart valve disease rising among U.S. adults ages 65 and older

Valvular heart disease mortality among U.S. adults aged 65 and older increased nearly 5% from 2018 to 2023, reversing a two-decade decline. Death rates rose from 104 to 109 per 100,000, with highest impact among men, non-Hispanic white adults, adults 85 and older, and nonmetropolitan residents.

Digest: Rising VHD mortality despite advances in transcatheter therapies signals potential gaps in early detection and access to valve interventions in aging and rural populations, informing market opportunity and healthcare delivery strategies.

AHAMarketGuidelinesRead original

Top Publications

View all research
No publications yet.
Conference Watch

PCR London Valves

Nov 22-24, 2026

London, United Kingdom

0d AWAY

Coming Up

Society of Thoracic Surgeons Annual Meeting

Jan 28-31, 2027 · New Orleans, LA

2mo

American College of Cardiology Scientific Session

Apr 10-12, 2027 · Houston, TX

5mo

EuroPCR

May 18-21, 2027 · Paris, France

6mo

New York Valves Structural Heart Summit

Jun 23-25, 2027 · New York, NY

7mo

Transcatheter Cardiovascular Therapeutics

Oct 18-21, 2027 · San Francisco, CA

11mo
View conference details